English

The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share

Report this content

Phase Holographic Imaging PHI AB ("PHI" or "the Company") hereby announces that the exercise price for the warrants of series TO 4 (”TO 4”), which were issued in connection with the rights issue of units that the Company executed during 2022, has been set. The exercise price for TO 4 has been set to SEK 4.63 per share and the exercise period commences on September 12, 2024.

In the Spring of 2022, PHI carried out a rights issue which brought the Company approximately SEK 57.6 million before issue costs. Through the rights issue, 1,346,162 warrants of series TO 4 were issued. Each TO 4 entitles the holder to subscribe for one (1) new share in PHI during the exercise period, which runs September 12-October 3, 2024. The exercise price for TO 4 has been set at SEK 4.63 per share. In the event of full utilization of warrants of series TO 4, approximately SEK 6.2 million will be added to the Company before issue costs.

Upon full utilization of TO 4, the number of shares in PHI will increase by 1,346,162 shares to a total of 27,539,087 shares, and the share capital will increase by SEK 269,232.40, to SEK 5,507,817.40. The dilution at full utilization amounts to approximately 4.9 percent of the capital and votes.

Complete terms and conditions for warrants of series TO 4 are available on the Company's website (www.phiab.com). An information sheet containing summary information about the warrant exercise will be available on PHI’s, Sedermera Corporate Finance AB's (www.sedermera.se) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites in connection with the initiation of the exercise period.

Important dates

  • 12 September 2024: Exercise period commences
  • 1 October 2024: Last day of trading in TO 4
  • 3 October 2024: Exercise period ends
  • 4 October 2024: Planned date for publication of outcome of the exercise
  • 18 October 2024: Planned date for change from interim shares to shares

Advisors

In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se

For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.  

Subscribe